EUCTR2005-002692-33-IT进行中（未招募）不适用
A randomized, Double blind, Placebo controlled phase 3 Study of the phosphodiesterae Type 5 PDE Inhibiotr Tadalafil in the Treatment of patients with Pulomanry Arterial Hypertension.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ELI LILLY
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
2 期
A randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 ASCI in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomybladder cancer: malignant tumor of bladderbladdercarcinoma10004994NL-OMON39841European Association of Urology25
进行中（未招募）
1 期
Safety and Efficacy study of recMAGE-A3 injection in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomy.Patients who get a cystectomy due to muscle invasive bladder cancer which is MAGE-A3 positiveMedDRA version: 14.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024355-85-NLEAU Research Foundation273
进行中（未招募）
1 期
Safety and Efficacy study of recMAGE-A3 injection in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomy.Patients who get a cystectomy due to muscle invasive bladder cancer which is MAGE-A3 positiveMedDRA version: 19.0Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2010-024355-85-DEEAU Research Foundation273
进行中（未招募）
1 期
A randomized, double blind, placebo controlled phase II evaluation of the pharmacokinetics, pharmacodynamics and safety of DG-041 in PAD patients - N/APeripheral arterial diseaseEUCTR2006-001368-22-ISdeCODE genetics ehf.210
进行中（未招募）
1 期
Safety and Efficacy study of recMAGE-A3 injection in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomy.Patients who get a cystectomy due to muscle invasive bladder cancer which is MAGE-A3 positiveMedDRA version: 14.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2010-024355-85-CZEAU Research Foundation273